AcouSort AB (publ) (ACOU.ST)
SEK 3.76
(0.27%)
SEK 3.76
(0.27%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -17.08 Million SEK | -29.35% |
| 2022 | -13.21 Million SEK | -6.7% |
| 2021 | -12.38 Million SEK | -50.62% |
| 2020 | -8.22 Million SEK | 15.11% |
| 2019 | -9.68 Million SEK | -8.07% |
| 2018 | -8.96 Million SEK | -47.56% |
| 2017 | -6.07 Million SEK | -631.57% |
| 2016 | -830 Thousand SEK | -197.65% |
| 2015 | -278.84 Thousand SEK | -358.17% |
| 2014 | 108 Thousand SEK | 272.21% |
| 2013 | -62.72 Thousand SEK | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | -4.71 Million SEK | -26.41% |
| 2024 Q1 | -3.72 Million SEK | 43.1% |
| 2023 Q2 | -3.19 Million SEK | -9.88% |
| 2023 Q4 | -6.55 Million SEK | -52.31% |
| 2023 FY | -17.08 Million SEK | -29.35% |
| 2023 Q3 | -4.3 Million SEK | -34.76% |
| 2023 Q1 | -2.9 Million SEK | -24.51% |
| 2022 FY | -13.21 Million SEK | -6.7% |
| 2022 Q4 | -2.33 Million SEK | 44.68% |
| 2022 Q3 | -4.21 Million SEK | -4.61% |
| 2022 Q2 | -4.03 Million SEK | -53.58% |
| 2022 Q1 | -2.62 Million SEK | 26.75% |
| 2021 Q4 | -3.58 Million SEK | -3.82% |
| 2021 Q1 | -1.68 Million SEK | 50.51% |
| 2021 Q2 | -3.47 Million SEK | -106.29% |
| 2021 Q3 | -3.45 Million SEK | 0.66% |
| 2021 FY | -12.38 Million SEK | -50.62% |
| 2020 Q3 | -2.21 Million SEK | -65.47% |
| 2020 FY | -8.22 Million SEK | 15.11% |
| 2020 Q1 | -1.02 Million SEK | 68.11% |
| 2020 Q2 | -1.33 Million SEK | -30.92% |
| 2020 Q4 | -3.4 Million SEK | -53.79% |
| 2019 Q2 | -3.12 Million SEK | -96.98% |
| 2019 FY | -9.68 Million SEK | -8.07% |
| 2019 Q4 | -3.2 Million SEK | -84.3% |
| 2019 Q3 | -1.73 Million SEK | 44.37% |
| 2019 Q1 | -1.58 Million SEK | 45.76% |
| 2018 Q1 | -2.26 Million SEK | -4.24% |
| 2018 Q4 | -2.92 Million SEK | -39.2% |
| 2018 FY | -8.96 Million SEK | -47.56% |
| 2018 Q3 | -2.1 Million SEK | -25.94% |
| 2018 Q2 | -1.66 Million SEK | 26.25% |
| 2017 Q3 | -1.28 Million SEK | 26.4% |
| 2017 FY | -6.07 Million SEK | -631.57% |
| 2017 Q1 | -864 Thousand SEK | 1.93% |
| 2017 Q2 | -1.75 Million SEK | -102.55% |
| 2017 Q4 | -2.17 Million SEK | -68.56% |
| 2016 Q3 | 134 Thousand SEK | 191.3% |
| 2016 FY | -830 Thousand SEK | -197.65% |
| 2016 Q1 | -117 Thousand SEK | 45.8% |
| 2016 Q4 | -881 Thousand SEK | -757.46% |
| 2016 Q2 | 46 Thousand SEK | 139.32% |
| 2015 Q4 | -215.84 Thousand SEK | -240.16% |
| 2015 Q3 | 154 Thousand SEK | 0.0% |
| 2015 FY | -278.84 Thousand SEK | -358.17% |
| 2014 FY | 108 Thousand SEK | 272.21% |
| 2013 FY | -62.72 Thousand SEK | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Asarina Pharma AB (publ) | -12.82 Million SEK | -33.216% |
| BioArctic AB (publ) | 229.24 Million SEK | 107.454% |
| Modus Therapeutics Holding AB (publ) | -17.89 Million SEK | 4.515% |
| CombiGene AB (publ) | -35.66 Million SEK | 52.085% |
| Diamyd Medical AB (publ) | -151.85 Million SEK | 88.746% |
| Elicera Therapeutics AB (publ) | -16.39 Million SEK | -4.214% |
| OncoZenge AB (publ) | -15.9 Million SEK | -7.464% |
| Alligator Bioscience AB (publ) | -248.58 Million SEK | 93.126% |
| Calliditas Therapeutics AB (publ) | -466.18 Million SEK | 96.334% |
| Mendus AB (publ) | -101.61 Million SEK | 83.183% |
| LIDDS AB (publ) | -40.2 Million SEK | 57.496% |
| Lipum AB (publ) | -37.17 Million SEK | 54.035% |
| Magle Chemoswed Holding AB (publ) | 12.16 Million SEK | 240.431% |
| Simris Alg AB (publ) | -37.3 Million SEK | 54.191% |
| Spago Nanomedical AB (publ) | -42.22 Million SEK | 59.527% |
| Stayble Therapeutics AB (publ) | -23.73 Million SEK | 28.007% |
| Xbrane Biopharma AB (publ) | -388.17 Million SEK | 95.598% |
| Xspray Pharma AB (publ) | -179.66 Million SEK | 90.489% |
| Ziccum AB (publ) | -21.41 Million SEK | 20.19% |
| Active Biotech AB (publ) | -45.8 Million SEK | 62.688% |
| Alzinova AB (publ) | -16.48 Million SEK | -3.695% |
| Amniotics AB (publ) | -30.87 Million SEK | 44.642% |
| Camurus AB (publ) | 431.44 Million SEK | 103.961% |
| Cantargia AB (publ) | -280.02 Million SEK | 93.897% |
| Scandinavian ChemoTech AB (publ) | -21.09 Million SEK | 18.975% |
| Genovis AB (publ.) | 61.5 Million SEK | 127.787% |
| Guard Therapeutics International AB (publ) | -113.32 Million SEK | 84.92% |
| Isofol Medical AB (publ) | -37.07 Million SEK | 53.902% |
| Intervacc AB (publ) | -102.85 Million SEK | 83.385% |
| Kancera AB (publ) | -64.88 Million SEK | 73.664% |
| Karolinska Development AB (publ) | 5.38 Million SEK | 417.286% |
| Lipigon Pharmaceuticals AB (publ) | -12.12 Million SEK | -40.905% |
| NextCell Pharma AB | -41.95 Million SEK | 59.273% |
| Saniona AB (publ) | -95.81 Million SEK | 82.164% |
| Vicore Pharma Holding AB (publ) | -310.94 Million SEK | 94.504% |
| Xintela AB (publ) | -54.08 Million SEK | 68.402% |
| Sprint Bioscience AB (publ) | -438 Thousand SEK | -3801.598% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | -16.52 Million SEK | -3.426% |
| Corline Biomedical AB | -1.8 Million SEK | -844.666% |
| IRLAB Therapeutics AB (publ) | -177.83 Million SEK | 90.391% |
| Bio-Works Technologies AB (publ) | -56.82 Million SEK | 69.925% |
| Aptahem AB (publ) | -11.11 Million SEK | -53.777% |
| Infant Bacterial Therapeutics AB (publ) | -123.06 Million SEK | 86.114% |
| Fluicell AB (publ) | -26.55 Million SEK | 35.644% |
| Biovica International AB (publ) | -124.82 Million SEK | 86.309% |
| Abliva AB (publ) | -95.5 Million SEK | 82.107% |
| Egetis Therapeutics AB (publ) | -326.9 Million SEK | 94.772% |
| 2cureX AB (publ) | -32.51 Million SEK | 47.448% |
| I-Tech AB | 20.2 Million SEK | 184.586% |
| Hansa Biopharma AB (publ) | -831.72 Million SEK | 97.945% |
| Cyxone AB (publ) | -22.98 Million SEK | 25.664% |
| ExpreS2ion Biotech Holding AB (publ) | -91.4 Million SEK | 81.303% |
| Biosergen AB | -27.03 Million SEK | 36.794% |
| Nanologica AB (publ) | -75.15 Million SEK | 77.262% |
| SynAct Pharma AB | -215.81 Million SEK | 92.081% |
| Annexin Pharmaceuticals AB (publ) | -44.05 Million SEK | 61.209% |
| BioInvent International AB (publ) | -330.3 Million SEK | 94.826% |
| Oncopeptides AB (publ) | -249.11 Million SEK | 93.14% |
| Pila Pharma AB (publ) | -9.93 Million SEK | -72.095% |
| Ascelia Pharma AB (publ) | -109.28 Million SEK | 84.363% |
| Diagonal Bio AB (publ) | -11.67 Million SEK | -46.335% |